참고문헌
-
Abshagen, U., 1987. A new molecule with vasodilating and
${\beta}$ -adrenoceptor blocking properties. J. Cardiovasc. Pharmacol. 10, 23-32. - Alarcon de la Lastra, C., Martin, M.J., Motilva, V., 1994. Antiulcer and gastroprotective effects of quercetin: a gross and histologic study. Pharmacology 48, 5662.
- Bart, J., Dijkers, E.C., Wegman, T.D., de Vries, E.G., van der Graaf, W.T., Groen, H.J., Vaalburg, W., Willemsen, A.T., Hendrikse, N.H., 2005. New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics. Br. J. Pharmacol. 145, 1045-51. https://doi.org/10.1038/sj.bjp.0706283
- Benet, L.Z., Cummins, C.L., Wu, C.Y., 2003. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. 4, 393-398. https://doi.org/10.2174/1389200033489389
- Bristow, M.R., Gilbert, E.M., Abraham, W.T., Adams, K.F., Fowler, M.B., Hershberger, R.E., Kubo, S.H., Narahara, K.A., Ingersoll, H., Krueger, S., Young, S., Shusterman, N., 1996. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94, 2807-2816. https://doi.org/10.1161/01.CIR.94.11.2807
- Bristow, M.R., Larrabee, P., Minobe, W., Roden, R., Skerl, L., Klein, J., Handwerger, D., Port, J.D., Müller-Beckmann, B., 1992. Receptor pharmacology of carvedilol in the human heart. J. Cardiovasc. Pharmacol. 19, S68-80. https://doi.org/10.1097/00005344-199219001-00014
- Cao, X., Gibbs, S.T., Fang, L., Miller, H.A., Landowski, C.P., Shin, H.C., Lennernas, H., Zhong, Y., Amidon, G.L., Yu, L.X., Sun, D., 2006. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23, 1675-1686. https://doi.org/10.1007/s11095-006-9041-2
- Cleland, J.G., Bristow, M.R., Erdmann, E., Remme, W.J., Swedberg, K., Waagstein, F., 1996. Beta-blocking agents in heart failure. Should they be used and how? Eur. Heart J. 17, 1629-1639. https://doi.org/10.1093/oxfordjournals.eurheartj.a014745
- Cournot, A., Lim, C., Duchier, J., Safar, M., 1992. Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects. J. Cardiovasc. Pharmacol. 19, S35-39.
- Crespi, C.L., Miller, V.P., Penman, B.W., 1997. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248, 188-190. https://doi.org/10.1006/abio.1997.2145
- Cummins, C.L., Jacobsen, W., Benet, L.Z., 2002. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 300, 1036-1045. https://doi.org/10.1124/jpet.300.3.1036
- DasGupta, P., Broadhurst, P., Lahiri, A., 1991. The effects of intravenous carvedilol, a new multiple action vasodilatory betablocker, in congestive heart failure. J. Cardiovasc. Pharmacol. 18, S12-16.
- Dixon, R.A., Steel, C.L., 1999. Flavonoids and isoflavonoids - a gold mine for metabolic engineering. Trend Plant. Sci. 4, 394-400. https://doi.org/10.1016/S1360-1385(99)01471-5
- Dzubak, P., Hajduch, M., Gazak, R., Svobodova, A., Psotova, J., Walterova, D., Sedmera, P., Kren, V., 2006. New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. Bioorg. Med. Chem. 14, 3793-3810. https://doi.org/10.1016/j.bmc.2006.01.035
- Feuerstein, G.Z., Bril, A., Ruffolo, R.R.Jr., 1997. Protective effects of carvedilol in the myocardium. Am. J. Cardiol. 80, 41L-45L. https://doi.org/10.1016/S0002-9149(97)00847-3
- Frishman, W.H., 1998. Carvedilol. N. Engl. J. Med. 339, 1759-1765. https://doi.org/10.1056/NEJM199812103392407
- Hampton, J.R., 1996. Beta-blockers in heart failure--the evidence from clinical trials. Eur. Heart J. 17, 17-20. https://doi.org/10.1093/eurheartj/17.suppl_B.17
- Kaminsky, L.S., Fasco, M.J., 1991. Small intestinal cytochromes P450. Crit. Rev. Toxicol. 21, 407-422.
- Katiyar, S.K., Korman, N.J., Mukhtar, H., Agarwal, R., 1997. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J. Natl. Cancer Inst. 89, 556-566. https://doi.org/10.1093/jnci/89.8.556
- Kolars, J.C., Schmiedlin-Ren, P., Schuetz, J.D., Fang, C., Watkins, P.B., 1992. Identification of rifampin-inducible P450IIIA4 (CYP2C9) in human small bowel enterocytes. J. Clin. Invest. 90, 1871-1878. https://doi.org/10.1172/JCI116064
- Kosina, P., Maurel, P., Ulrichova, J., Dvorak, Z., 2005. Effect of silybinin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. J. Biochem. Mol. Toxicol. 19, 149-153. https://doi.org/10.1002/jbt.20066
- Lewis, D.F.V., 1996. Cytochrome P450. Substrate specificity and metabolism. In: Cytochromes P450. Structure, Function, and Mechanism. Taylor & Francis: Bristol. 122-123.
- Lund-Johansen, P., Omvik, P., Nordrehaug, J.E., White, W., 1992. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure. J. Cardiovasc. Pharmacol. 19, S27-34. https://doi.org/10.1097/00005344-199219001-00007
- McTavish, D., Campoli-Richards, D., Sorkin, E.M., 1993. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 45, 232-58.
- Morazzoni, P., Bombardelli, E., 1995. Silybum marianum (fitoterapia). Fitoterapia 66, 3-42.
- Morgan, T., 1994. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin. Pharmacokinet. 26, 335-346. https://doi.org/10.2165/00003088-199426050-00002
- Neugebauer, G., Akpan, W., von Mollendorff, E., Neubert, P., Reiff, K., 1987. Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Pharmacol. 11, S85-88.
- Neugebauer, G., Neubert, P., 1991. Metabolism of carvedilol in man. Eur. J. Drug Metab. Pharmacokinet. 16, 257-260. https://doi.org/10.1007/BF03189969
- Nijveldt, R.J., van Nood, E., van, Hoorn, D.E., Boelens, P.G., van Norren, K., van Leeuwen, P.A., 2001. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74, 418-425.
- Ohnishi, E., Bannai, H., 1993. Quercetin potentiates TNF-induced antiviral activity. Antiviral Res. 22, 327-331. https://doi.org/10.1016/0166-3542(93)90041-G
- Oldham, H.G., Clarke, S.E., 1997. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab. Dispos. 25, 970-977.
- Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., Komano, T., 1993. Pglycoprotein- mediated transcellular transport of MDR-reversing agents. FEBS. Lett. 324, 99-102. https://doi.org/10.1016/0014-5793(93)81540-G
- Takahama, U., 1985. Inhibition of lipoxygenase-dependent lipid peroxidation by quercetin: mechanism of antioxidative function. Phytochemistry 24, 1443-1446. https://doi.org/10.1016/S0031-9422(00)81040-7
- von Mollendorff, E., Abshagen, U., Akpan, W., Neugebauer, G., Schroter, E., 1986. Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity. Clin. Pharmacol. Ther. 39, 677-682. https://doi.org/10.1038/clpt.1986.118
- Zhao, J., Lahiri-Chatterjee, M., Sharma, Y., Agarwal, R., 2000. Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin. Carcinogenesis 21, 811-816. https://doi.org/10.1093/carcin/21.4.811
- Zharghi, A., Foroutan, S.M., Shafaati, A., Khoddam, A., 2007. Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: Application in pharmacokinetic studies. J. Pharm. Biomed. Anal. 44, 250-253. https://doi.org/10.1016/j.jpba.2007.01.026
- Zuber, R., Modriansky, M., Dvorak, Z., Rohovsky, P., Ulrichova, J., Simanek, V., Anzenbacher, P., 2002. Effect of silybinin and its congeners on human liver microsomal cytochrome P450 activities. Phytother. Res. 16, 632-638. https://doi.org/10.1002/ptr.1000